Tag Archive for: drug development

AI makes headlines again as Insilico signs another major licensing deal

#AI has been making the headlines again this week, with a bold announcement from the UK government that it could be used to fix the many potholes that pepper Britain’s roads.  But beyond politics, there’s an ongoing narrative in life sciences about the growing role of AI across the clinical development process.  Perhaps the most […]

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]

General Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological search

Enable Medicine is at the forefront of using generative AI models to search vast cellular atlases of disease to discover new therapeutic insights Partnership will greatly boost the two companies’ drug discovery and development capabilities It comes after their first collaboration that led to Ennovate Pharma SAS, working on highly promising targets in autoimmune and […]

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General […]

Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium

Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to […]